Cell line · CVCL_3172
Papers45
1 to 20 of 45
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chrysosplenetin-induced TMED3 aggregation triggers unfolded protein response in pancreatic cancer. | EMBO Mol Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MYC-Mediated USP39 Upregulation Stabilizes SRSF1 in Pancreatic Cancer. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sustained reductions in valine and isoleucine mediate anti-cancer pharmacological effects of inhibiting amino acid transporter LAT1 in cancer cells. | Cancer Metab | 2025 | Its Methods give the RRID and name the line | PubMed | |
| KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Integrated spatial morpho-transcriptomics predicts functional traits in pancreatic cancer. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Stiff extracellular matrix activates the transcription factor ATF5 to promote the proliferation of cancer cells. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. | Cell Death Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer. | Cancers (Basel) | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Combined Targeting of NAD Biosynthesis and the NAD-dependent Transcription Factor C-terminal Binding Protein as a Promising Novel Therapy for Pancreatic Cancer. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Novel positron emission tomography imaging targeting cell surface glycans for pancreatic cancer: 18 F-labeled rBC2LCN lectin. | Cancer Sci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Lectin-based phototherapy targeting cell surface glycans for pancreatic cancer. | Int J Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator. | Cancers (Basel) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. | Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. | J Exp Clin Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3172/papers